AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18211256
Drug: Obstetric gel
RxNorm normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstetric gel use
Trial: 18211256
Drug: No obstetric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No obstetric gel use (Control)
Trial: 8402658
Drug: 4‐HPR 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐HPR 200 mg/daily
Trial: 2876722
Drug: Bisoprolol (2.5-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (2.5-40 mg)
Trial: 2876722
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 and 80 mg)
Trial: 2905149
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 and 100 mg)
Trial: 2876722
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 and 100 mg)
Trial: 26994397
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy for ultra-high risk (CBTuhr)
Trial: 22116378
Drug: Yohimbine hydrochloride
RxNorm normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine hydrochloride (10 mg) combined with virtual reality exposure therapy (VRET)
Trial: 22116378
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with virtual reality exposure therapy (VRET)
Trial: 18640889
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (AI) such as anastrozole or letrozole for 5 years
Trial: 18640889
Drug: Sequential approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential approach of tamoxifen for 2-3 years followed by anastrozole or exemestane for 2-3 years
Trial: 10100179
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive preparation (20 micrograms of ethinyl estradiol plus 0.15 mg desogestrel)
Trial: 8961507
Drug: PFP-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFP-2 vaccine
Trial: 8684872
Drug: Saline vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline vaccine (control)
Trial: 1516602
Drug: Defibrotide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide 400 mg b.d. for 30 days
Trial: 6408669
Drug: Desipramine (150‐350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150‐350 mg/day)
Trial: 30001195
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of extra-amniotic Foley's catheter inflated by 30 cm3 of normal saline and 25 micrograms of vaginal misoprostol
Trial: 30001195
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of extra-amniotic Foley's catheter and vaginal misoprostol
Trial: 2799651
Drug: 1 gm
RxNorm normalized name: Ifex 1 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gm cefazolin in buttock fat, buttock muscle, or by intravenous injection
Trial: 1095040
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg diazepam
Trial: 1095040
Drug: 0.30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 mg/kg diazepam
Trial: 1095040
Drug: 0.45 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/kg diazepam
Trial: 19808140
Drug: Temsirolimus (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (25 mg) administered as a 30-minute intravenous infusion
Trial: 19808140
Drug: Temsirolimus (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (25 mg) administered as a 30-minute intravenous infusion in patients receiving hemodialysis
Trial: 1763796
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms of vaccine
Trial: 1455910
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of vaccine
Trial: 1763796
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of vaccine
Trial: 1763796
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms of vaccine
Trial: 6130077
Drug: Buspirone (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (30, 60, and 90 mg)
Trial: 29231094
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg once daily after 5 days of low-molecular-weight heparin)
Trial: 29231094
Drug: Dalteparin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (200 IU/kg once daily for 1 month followed by 150 IU/kg once daily)
Trial: 24562789
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (cohort II)
Trial: 23197976
Drug: Dipeptidyl peptidase-4
RxNorm normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dipeptidyl peptidase-4 inhibitor (vildagliptin)
Trial: 16806875
Drug: daily rhDNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily rhDNase
Trial: 9871843
Drug: TRH (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (0.4 mg intravenous bolus)
Trial: 8714022
Drug: Pulsatile intravenous
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile intravenous administration of oxytocin (OT)
Trial: 8714022
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous administration of oxytocin (OT)
Trial: 27997954
Drug: Intensive Language
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Language Action Therapy (ILAT)
Trial: 24389597
Drug: Atorvastatin (20mg/day)
RxNorm normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20mg/day) for 30 days
Trial: 22353460
Drug: Oral‐B Stages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Stages 3 toothbrush (MTB)
Trial: 17955096
Drug: Lamotrigine with
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine with concomitant antipsychotics
Trial: 17955096
Drug: Lamotrigine with
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine with concomitant valproate, lithium, or antidepressants
Trial: 16274805
Drug: Lipid-based nose
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nose ointment
Trial: 10542930
Drug: Subgroup with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup with fasting lipids > 6.5 mmol/l
Trial: 1699888
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.33% bupivacaine (20 ml 0.5% bupivacaine + 10 ml of N saline)
Trial: 1699888
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.5% bupivacaine + 10 ml of dextraven-150 (6% solution in 5% dextrose)
Trial: 356237
Drug: Proquazone (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proquazone (900 mg daily for 3 weeks)
Trial: 356237
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg daily for 3 weeks)
Trial: 31987456
Drug: Mechanism-based agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanism-based agents applied in rare cancers
Trial: 25760065
Drug: Desensitizing gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desensitizing gel applied once per week until remission of pain (T1)
Trial: 25760065
Drug: Desensitizing gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desensitizing gel applied once per week followed immediately by restoration with resin composite (T2)
Trial: 25760065
Drug: Desensitizing gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desensitizing gel once per week until remission of pain and then restoration with resin composite (T3)
Trial: 22338171
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (MTX) at 10 mg plus low-dose methylprednisolone (MP) at 0.5 mg x kg(‐1) x d(‐1) in Group A
Trial: 22338171
Drug: Standard-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose methylprednisolone (MP) at 1-2 mg x kg(‐1) x d(‐1) in Group B
Trial: 17705571
Drug: Manidipine 10-20
RxNorm normalized name: manidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manidipine 10-20 mg once daily
Trial: 15385735
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg/d for 30 days)
Trial: 3612823
Drug: Barbach's preorgasmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barbach's preorgasmic treatment program
Trial: 29244528
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib (LAP) + Trastuzumab (TRAS) + Aromatase Inhibitor (AI)
Trial: 29244528
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib (LAP) + Aromatase Inhibitor (AI)
Trial: 29244528
Drug: Trastuzumab (TRAS)
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (TRAS) + Aromatase Inhibitor (AI)
Trial: 28479001
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg 3 times a day
Trial: 28479001
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg 3 times a day
Trial: 26630680
Drug: 5‐methylenetetrahydrofolate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐methylenetetrahydrofolate (1 mg daily)
Trial: 30283911
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 mg daily)
Trial: 17159119
Drug: Apraxia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apraxia treatment
Trial: 17159119
Drug: Control (aphasia)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (aphasia) treatment
Trial: 15504842
Drug: Indinavir/ritonavir (IDV/RTV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir/ritonavir (IDV/RTV) at 667/100 mg every 12 hours
Trial: 15504842
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indinavir (IDV) alone at 800 mg every 8 hours
Trial: 11174287
Drug: Intraluminal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraluminal administration of peppermint oil (200 mL solution: 8 mL peppermint oil + 0.2 mL Tween 80 per 1 L water with 0.04% indigo carmine)
Trial: 11174287
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (solution without peppermint oil)
Trial: 9430090
Drug: Dietary sitosterol
RxNorm normalized name: sitosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary sitosterol intake increased to 1.8 mg/kg, 2.6 mg/kg, and 3.5 mg/kg/day in the homozygote after a basal low-sitosterol diet (33 mg per 2000 kcal).
Trial: 30264119
Drug: Algorithm-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-based therapy (n=255)
Trial: 22572889
Drug: Lu AA21004
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AA21004 5 mg/day
Trial: 20942269
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine administration (combined with intrathecal bupivacaine)
Trial: 21784372
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg plus ezetimibe 10 mg
Trial: 16140027
Drug: Inhaled bimosiamose
RxNorm normalized name: Bimosiamose
DrugBank: Bimosiamose (DB06197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bimosiamose 70 mg bid on days 1-3 and 70 mg once on the morning of day 4
Trial: 10444051
Drug: High oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oxygen transmissibility (Dk/L) RGP lenses for 12 months of extended wear
Trial: 10444051
Drug: Reasons for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reasons for failure to adapt to RGP daily wear
Trial: 2801572
Drug: Nicardipine 2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 2.5, 5.0, and 10.0 mg intravenous
Trial: 4271320
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with immunotherapy (multiple weekly intradermal injections of irradiated stored AML cells and Glaxo B.C.G.)
Trial: 31754882
Drug: Dotinurad 4
RxNorm normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Dotinurad 4 mg
Trial: 28287476
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice containing 409 mg total (poly)phenols
Trial: 28287476
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice containing 787 mg total (poly)phenols
Trial: 28287476
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice containing 1238 mg total (poly)phenols
Trial: 28287476
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice containing 1534 mg total (poly)phenols
Trial: 28287476
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice containing 1910 mg total (poly)phenols
Trial: 28287476
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (all doses)
Trial: 25249405
Drug: Weight, waist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight, waist or hip circumferences, insulin levels, high triglycerides (TG), low high-density lipoprotein (HDL)
Trial: 23711600
Drug: IV-PCA morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-PCA morphine plus intra- and postoperative ketamine and clonidine premedication (MCK)
Trial: 23711600
Drug: IV-PCA morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-PCA morphine alone (M)
Trial: 23711600
Drug: IV-PCA morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-PCA morphine plus oral clonidine premedication (MC)
Trial: 23711600
Drug: IV-PCA morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV-PCA morphine plus intra- and postoperative ketamine (MK)
Trial: 19572992
Drug: Parenteral ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral ampicillin (P‐Ab)
Trial: 19572992
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (O‐Ab)
Trial: 19572992
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (N‐Ab)
Trial: 1164639
Drug: Clobetasone butyrate
RxNorm normalized name: clobetasone butyrate
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Clobetasone butyrate 0.05% ointment
Trial: 11479164
Drug: Short daily
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short daily hemodialysis (DHD)
Trial: 8001208
Drug: mivacurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.15 mg.kg‐1 as a single bolus dose
Trial: 8001208
Drug: mivacurium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.015 mg.kg‐1 followed by mivacurium 0.135 mg.kg‐1
Trial: 8001208
Drug: rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.6 mg.kg‐1 as a single bolus dose
Trial: 8001208
Drug: rocuronium 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.06 mg.kg‐1 followed by rocuronium 0.54 mg.kg‐1
Trial: 8001208
Drug: mivacurium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.015 mg.kg‐1 followed by rocuronium 0.54 mg.kg‐1
Trial: 8001208
Drug: rocuronium 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.06 mg.kg‐1 followed by mivacurium 0.135 mg.kg‐1
Trial: 8001208
Drug: succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 1.0 mg.kg‐1
Trial: 25876346
Drug: Scalp acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp acupuncture and EEG biofeedback therapy (combined therapy)
Trial: 25876346
Drug: EEG biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG biofeedback therapy (control group)
Trial: 21750460
Drug: Botox injection
RxNorm normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox injection
Trial: 21750460
Drug: Lidocaine/Depomedrol injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/Depomedrol injection
Trial: 20010618
Drug: valsartan/HCTZ 160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan/HCTZ 160/12.5 mg (V/HCTZ)
Trial: 20010618
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg (V-low)
Trial: 20010618
Drug: valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 160 mg (V-high)
Trial: 31529406
Drug: Atacicept (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (all doses)
Trial: 30481790
Drug: Ophthalmic insert
RxNorm normalized name: OPHTHALMIC INSERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic insert Mydriasert®
Trial: 24437167
Drug: Sublingual dose
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual dose of nitrates (nitroglycerin and mononitrate isosorbide)
Trial: 19633827
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering treatment with perindopril-indapamide (n = 623)
Trial: 11303848
Drug: Cefepime 50
RxNorm normalized name: cefepime 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 50 mg/kg/dose administered every 8 to 12 hours
Trial: 11303848
Drug: Ceftazidime, Cefotaxime,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime, Cefotaxime, Cefuroxime (comparator therapy)
Trial: 8491068
Drug: Remikiren (intravenous)
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren (intravenous) at doses of 10, 20, 40, 80, 160, and 320 mg
Trial: 8491068
Drug: Remikiren (oral)
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren (oral) at doses of 100, 200, 400, 800, and 1600 mg
Trial: 8491068
Drug: Remikiren (oral)
RxNorm normalized name: remikiren
DrugBank: Remikiren (DB00212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren (oral) at 1600 mg
Trial: 3329766
Drug: Choline magnesium
RxNorm normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choline magnesium trisalicylate (CMT) 655 mg
Trial: 3329766
Drug: Acetyl salicylic
RxNorm normalized name: Acetyl salicylic acid specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl salicylic acid (ASA) 652 mg
Trial: 26684923
Drug: Ultra-low-dose buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose buprenorphine (initial dosage 0.1 mg once or twice daily; mean final dosage 0.44 mg/day)
Trial: 24441865
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing (OD) of amikacin (15 or 20 mg/kg)
Trial: 24441865
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing (TD) of amikacin (15 or 20 mg/kg)
Trial: 24441865
Drug: Amikacin pharmacokinetics
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin pharmacokinetics
Trial: 24441865
Drug: Amikacin dosing
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin dosing based on neonatal age
Trial: 22251022
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to an alternate antidepressant (venlafaxine)
Trial: 22251022
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to an alternate SSRI plus cognitive behavior therapy (CBT)
Trial: 18534618
Drug: Inhaled CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled CO2 (0.8%) for 2 hours
Trial: 15668285
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan at a dose of 70 mg/m(2) days 1, 8, 15, 22, 29 in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks (arm A)